Global Recombinant Chemicals Market Size Study, by Product Type (Recombinant Proteins, Recombinant DNAs, Recombinant Peptides, Others), by Technology (Microbial Expression Systems, Mammalian Cell Expression Systems, Yeast Expression Systems, Insect Cell E

Global Recombinant Chemicals Market Size Study, by Product Type (Recombinant Proteins, Recombinant DNAs, Recombinant Peptides, Others), by Technology (Microbial Expression Systems, Mammalian Cell Expression Systems, Yeast Expression Systems, Insect Cell Expression Systems, Cell-free Expression Systems), by Application (Drug Development, Vaccine Production, Therapeutics, Cell Line Development, Agriculture, Food and Beverage, Others), and Regional Forecasts 2022-2032

The Global Recombinant Chemicals Market is valued at approximately USD 2.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2024-2032. Recombinant chemicals, produced through genetic engineering techniques, include recombinant proteins, DNAs, and peptides. Recombinant proteins are polypeptides produced from cloned genes and are widely employed in fields such as medicine, research, and biotechnology due to their advantages such as high purity, specificity, efficiency, safety, customization, scalability, and consistency. Recombinant proteins are used in vaccine development, therapeutics, diagnostics, and drug discovery and development. They include cytokines, enzymes, hormones, blood clotting factors, growth factors, monoclonal antibodies (mAbs), and antibody-related products. Recombinant protein vaccines are considered safer than vaccines derived from live viruses as they are non-replicating and lack infectious components.

The rise in demand for recombinant protein vaccines is significantly driving the market value of recombinant chemicals. Recombinant protein vaccines, which constitute a proven and well-established vaccine development platform, are particularly in demand due to the increased need for recombinant protein-based SARS-CoV-2 vaccines, thereby augmenting the demand for DNA-derived chemicals. The prevalence of genetic disorders is also fueling the recombinant chemicals market development. Medicinal products produced through recombinant DNA technology have revolutionized the treatment and management of various genetic disorders. Key players operating in the recombinant chemicals market are producing high-purity recombinant products for studying antibody and enzyme binding sites, as well as novel small therapeutics, drug agents, and vaccines.

Recombinant DNA technology, which involves the joining of DNA molecules from two different species, is gaining traction in the production of pharmaceutical and biotechnological products, including nutraceuticals. Products such as Elelyso, which contains the active substance taliglucerase alfa, are produced using recombinant DNA technology for the treatment of genetic disorders like type 1 Gaucher disease.

Key regions considered for the global Recombinant Chemicals Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. In 2023, North America stands out as the dominating region. This dominance is primarily driven by the presence of advanced biotechnology infrastructure, significant investments in research and development, and the presence of major pharmaceutical and biotech companies. Additionally, strong support from government initiatives and a high demand for biopharmaceuticals contribute to North America's leading position in this market. On the other hand, the Asia-Pacific region is the fastest-growing market for recombinant chemicals. The rapid growth in this region is fueled by increasing healthcare expenditures, a growing biotech industry, and rising investments in life sciences research. Countries like China and India are at the forefront of this growth due to their expanding pharmaceutical sectors, favorable government policies, and a rising focus on precision medicine. Additionally, the availability of a skilled workforce and the establishment of new biotech startups further accelerate the market expansion in the Asia-Pacific region.

Major market players included in this report are:
Genentech, Inc.
Amgen Inc.
Biogen
Pfizer, Inc.
Novartis AG
Merck & Co.
Sanofi
F. Hoffmann-La Roche AG
Johnson & Johnson Services, Inc.
Bayer AG
Mitsubishi Chemical Group
Bharat Serums and Vaccines (BSV)
Serum Institute of India
University of São Paulo (USP)
Oswaldo Cruz Foundation (FIOCRUZ)

The detailed segments and sub-segment of the market are explained below:
By Product Type:
Recombinant Proteins
Recombinant DNAs
Recombinant Peptides
Others

By Technology:
Microbial Expression Systems
Mammalian Cell Expression Systems
Yeast Expression Systems
Insect Cell Expression Systems
Cell-free Expression Systems

By Application:
Drug Development
Vaccine Production
Therapeutics
Cell Line Development
Agriculture
Food and Beverage
Others

By Region:
North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico
Rest of Latin America

Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2034

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.